Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence.
Journal Title: Annals of Hepatology - Year 2010, Vol 9, Issue 2
Abstract
Background. Patients who receive liver transplantation for chronic hepatitis B infection require long-term combination therapy with hepatitis B immunoglobulin (HBIG) and oral antiviral medication to prophylax against graft re-infection. This study examines the efficacy and patient preference of subcutaneous (SC) administration of HBIG in maintaining anti HBs titres > 100 IU/L. Materials and methods. 12 patients who were stable while receiving our standard IM HBIG protocol received an alternate formulation by SC injection, consisting of 10 mL (3120 IU) HBIG as 4 x 2.5 mL SC injections. SC injection were repeated as soon as titres reached 100-150 IU/mL during the 3 month study period. A questionnaire was administered upon study entry and exit to subjectively assess patient preference. Results. Anti- HBs Cmax after first injection was 441.6 IU/L ± 81.5, and Tmax was 7.1 ± 3.2 days. SC injections were required every 56 days, which compared well to the frequency of required IM injections prior to study enrollment of 45 days. The patients mean ratings of pain on a 0-10 scale were 5 for the IM route and 1.6 for the SC route. All patients preferred the SC injections to the IM. Conclusion. SC administration of HBIG can effectively maintain anti HBs levels above the requisite 100 IU/L while substantially decreasing patient discomfort and improving patient satisfaction, and therefore becomes a very attractive alternative to IM HBIG injections. Further studies and wider use of SC HBIG based on this study may alter the standard practice of transplantation centers
Authors and Affiliations
Janakie Singham, Erica Greanya, Kirby Lau, Siegfried Erb, Nilu Partovi, Eric Yoshida
Keywords
Related Articles
- EP ID EP77930
- DOI -
- Views 106
- Downloads 0
Efficacy and safety of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy
Background and aims. Patients with intrahepatic cholestasis of pregnancy (ICP) benefit from ursodeoxycholic acid (UDCA) treatment. Since there is still certain reluctance to use UDCA in pregnant women, mainly due to war...
Association of a novel TAS2R38 haplotype with alcohol intake among Mexican-Mestizo population
Background. Alcohol intake has been associated with the bitter taste receptor T2R38. TAS2R38 gene expresses two common haplotypes: PAV and AVI. It has been reported that AVI homozygotes consume more alcohol than heterozy...
Gene expression profiling reveals key genes and pathways related to the development of non-alcoholic fatty liver disease
Background. This study aims to identify key genes and pathways involved in non-alcoholic fatty liver disease (NAFLD). Materialand methods. The dataset GSE48452 was downloaded from Gene Expression Omnibus, including 14 c...
Andres Blei (Andy) October 1949-October 2008
Minimal hepatic encephalopathy. Should we treat it?